Skip to main content

Table 1 Sociodemographic and clinical characteristics and duration of follow-up for Medicare-eligible stage IV ER + breast cancer patients who did not receive HER2 targeted agents and matched comparison patients

From: Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data

Characteristic

Study cohort

Comparison cohort

P-value***

N

325

325

 

Age (years)*

   

  Mean ± SD

77.18 ± 7.19

77.26 ± 7.75

0.813

  Median

77.00

76.00

 

Race (%)*

  

1.000

  White

85.5%

85.5%

 

  Black

10.2%

10.2%

 

  Hispanic

0.6%

0.6%

 

  Asian

2.2%

2.2%

 

  Other

1.5%

1.5%

 

Urban (%)

99.1%

96.6%

0.055

Geographic region (%)

  

0.005

  Northeast

30.8%

19.1%

 

  Midwest

13.8%

12.9%

 

  West

34.8%

42.5%

 

  South

20.6%

25.2%

 

Duration of follow-up (months)

   

  Mean ± SD

18.12 ± 11.91

25.82 ± 8.94

< 0.001

  Median

20.00

28.00

 

Charlson score**

   

  Mean ± SD

1.12 ± 1.58

1.31 ± 1.71

0.072

  Median

1.00

1.00

 

Charlson comorbidities (%)

   

  Diabetes without chronic complications

25.8%

26.5%

0.929

  Chronic pulmonary disease

23.1%

20.3%

0.447

  Congestive heart failure

14.2%

12.0%

0.485

  Cerebrovascular disease

10.8%

16.3%

0.051

  Diabetes with chronic complications

7.7%

8.0%

1.000

  Renal disease

6.2%

7.1%

0.753

  Peripheral vascular disease

5.8%

8.9%

0.177

  Rheumatologic disease

4.3%

5.2%

0.713

  Myocardial infarction

3.7%

4.3%

0.842

  Dementia

2.2%

8.3%

< 0.001

  Peptic ulcer disease

0.9%

2.2%

0.340

  Hemiplegia or paraplegia

0.3%

1.8%

0.123

  Moderate or severe liver disease

0.3%

0.3%

1.000

  AIDS

0.0%

0.0%

< 0.001

  Mild liver disease

0.0%

0.6%

0.499

Other comorbidities (%)

   

  Depression/anxiety

9.2%

17.8%

0.002

  Osteoporosis/Fractures

14.5%

25.8%

< 0.001

PR status

   

  PR+

78.0%

n/a

 

  PR-

22.0%

n/a

 
  1. *Matching criteria.
  2. **Charlson score excludes any primary malignancy and metastatic solid tumor.
  3. ***Proportions were compared using the Fisher's exact test while continuous measures were compared using the nonparametric Wilcoxon test.